The Ottosson Group: Metabolomics

The human metabolome provides a comprehensive snapshot of metabolic alterations and is closely linked to various disease outcomes. Given the complex pathogenesis of inflammatory bowel disease (IBD), metabolomics—at the intersection of genetics, environmental factors, and the gut microbiome—holds great potential for uncovering the biochemical mechanisms driving disease development.

Metabolomics is expected to play a crucial role in understanding IBD, from its preclinical phase to disease progression and prognosis. The Ottosson group aims to deliver a comprehensive metabolomic characterization of IBD, spanning from early disease markers to long-term outcomes. This initiative is strengthened by collaborations within PREDICT and international institutions, integrating metabolomics with national registers, nutritional, genetic, and proteomic data to pave the way for novel prevention strategies.

Dr. Filip Ottosson, PhD, is an Assistant Professor leading the Metabolomics group in collaboration with Professor Tine Jess, MD, DMSc. With a doctorate in Medical Sciences and extensive experience applying metabolomics to population studies, Dr.Ottosson has expertise in biochemistry, epidemiology, and statistics . He has authored multiple high-impact publications linking the metabolome to cardiometabolic diseases, the gut microbiota, and diet. Now, he is dedicated to leveraging these approaches to advance the study of IBD.

Author ORCID: 0000-0002-8312-3545